Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy

J Thorac Oncol. 2022 Jul;17(7):862-864. doi: 10.1016/j.jtho.2022.05.005.

Authors

Azam Ghafoor¹, Raffit Hassan²

Affiliations

¹ Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
² Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: hassanr@mail.nih.gov.

PMID: 35750452
DOI: 10.1016/j.jtho.2022.05.005

No abstract available

Publication types

Editorial
Research Support, N.I.H., Intramural
Comment

MeSH terms

Biomarkers
Biomarkers, Tumor / genetics
Humans
Lung Neoplasms* / pathology
Mesothelioma* / pathology
Mesothelioma, Malignant*
Pleural Neoplasms* / pathology
Tumor Suppressor Proteins / genetics
Ubiquitin Thiolesterase / genetics

Substances

BAP1 protein, human
Biomarkers
Biomarkers, Tumor
Tumor Suppressor Proteins
Ubiquitin Thiolesterase